Renal Cancer Studies

Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)

Study area = Kidney Cancer

Aim = The aim of the RAMPART study is to understand whether taking durvalumab alone, or in combination with tremelimumab, can prevent or delay kidney cancer coming back.

Who can participate = Any patients who have undergone surgery to remove their kidney cancer and who have a high or intermediate risk of their cancer coming back.

If you would like any further information on the following studies, and to find out if you are eligible please contact:


Address: R&D office, C254, West Wing, Broomfield Hospital, Court Road, Chelmsford, Essex, CM1 7ET

Telephone: 01245 515136
Email: Research@meht.nhs.uk